Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma

StatusRecruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 5 months later Aug 1, 2026 → Jan 31, 2027
See other at-risk trials from Robert Flavell, MD, PhD

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Aug 1, 2026 to Jan 31, 2027 Show 5 more changesShow less
    • Study completion pushed from Sep 1, 2026 to Mar 1, 2027
    • Interventions: Fludeoxyglucose F-18 (Other), Positron Emission Tomography / Computed Tomography (PET/CT) (Procedure), Positron Emission Tomography /… to Fludeoxyglucose F-18 (Other), Positron Emission Tomography / Computed Tomography (PET/CT) (Procedure), Positron Emission Tomography /…
    • Eligibility criteria shortened, about 13 words
    • Secondary endpoints: details revised at 3 of 4 entries
    • Study description revised
  2. Eligibility criteria revisedv6
  3. Eligibility criteria expanded, about 11 words
    • Site contact updated
    v5
  4. Eligibility criteria shortened, about 15 wordsv4
  5. Eligibility criteria revisedv3
  6. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 1, 2023 to Jun 16, 2023
    • Site details revised
    v2
  7. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase I trial tests the safety of \[89Zr\]DFO-YS5 positron emission tomography (PET) imaging and how well it works to detect CD46 positive cancer cells in patients with multiple myeloma. \[89Zr\]DFO-YS5 is an imaging agent called a radiopharmaceutical tracer. A radiopharmaceutical tracer uses a small amount of radioactive material that is injected into a vein to help image different areas of the body. \[89Zr\]DFO-YS5 targets a specialized protein called CD46, which is in certain multiple myeloma cancer cells, and \[89Zr\]DFO-YS5 PET scans may improve detection of multiple myeloma.
Trial Details
NCT Number NCT05892393
Lead Sponsor Robert Flavell, MD, PhD
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)		 Multiple Myeloma, Plasma Cell Myeloma
Related terms Multiple Myeloma
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov